AL003

TargetCD33

Modalitymonoclonal antibody

IndicationAlzheimer's disease

PhasePhase 1 (Discontinued)

PartnerAbbVie

Trial IDNCT03822208

Registry statusCOMPLETEDVerified 2026-10-05

Notes

AL003 was a monoclonal antibody directed against CD33, designed to block this inhibitory receptor and promote microglial phagocytosis of amyloid beta. The program was discontinued by AbbVie following Phase 1 evaluations.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: October 5, 2026